Diagnostic criteria and laboratory tests for disseminated intravascular coagulation

References

• Wada H. Disseminated intravascular coagulation. Clin. Chim. Acta 344(1–2), 13–21 (2004).
   PubMed Web of Science ®Google Scholar
• Colman RT, Robby SJ, Minna JD. Disseminated intravascular coagulation (DIC): an approach. Am. J. Med. 52, 679–689 (1974).
   Web of Science ®Google Scholar
• Al-Mondhiry H. Disseminated intravascular coagulation: experience in a major cancer center. Thromb. Diath. Haemorrh. 34(1), 181–193 (1975).
   PubMedGoogle Scholar
• Siegal T, Seligsohn U, Aghai E, Modan M. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb. Haemost. 39(1), 122–134 (1978).
   PubMed Web of Science ®Google Scholar
• Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb. Haemost. 43(1), 28–33 (1980).
   PubMed Web of Science ®Google Scholar
• Aoki N, Hasegawa H. About revised version of ‘Auxiliary test findings and results for diagnostic’ in diagnostic criteria for DIC: a study report by the research ommittee on blood coagulation on abnormalities in 1987. Special diseases designated by Japanese Ministry of Health and Welfare. 37–41 (1988).
   Google Scholar
• Warren BL, Eid A, Singer P et al.; KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286(15), 1869–1878 (2001).
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human protein C for severe sepsis. N. Engl. J. Med.. 8, 699–709 (2001).
   Google Scholar
• Abraham E, Reinhart K, Opal S et al.; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290(2), 238–247 (2003).
   PubMed Web of Science ®Google Scholar
• Aoki N, Matsuda T, Saito H et al.; CTC-111-IM Clinical Research Group. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int. J. Hematol. 75(5), 540–547 (2002).
   PubMed Web of Science ®Google Scholar
• Saito H, Maruyama I, Shimazaki S et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a Phase III, randomized, double-blind clinical trial. J. Thromb. Haemost. 5(1), 31–41 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 86(5), 1327–1330 (2001).
   PubMed Web of Science ®Google Scholar
• Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 268(24), 3452–3455 (1992).
   PubMed Web of Science ®Google Scholar
• Gando S, Iba T, Eguchi Y et al.; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit. Care Med. 34(3), 625–631 (2006).
   PubMed Web of Science ®Google Scholar
• Gando S, Wada H, Asakura H et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin. Appl. Thromb. Hemost. 11(1), 71–76 (2005).
   PubMed Web of Science ®Google Scholar
• Toh CH, Hoots WK; SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J. Thromb. Haemost. 5(3), 604–606 (2007).
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Gando S, Hoshino H. A prospective comparison of new Japanese criteria for disseminated intravascular coagulation: new Japanese criteria versus ISTH criteria. Clin. Appl. Thromb. Hemost. 13(2), 172–181 (2007).
   PubMed Web of Science ®Google Scholar
• Egi M, Morimatsu H, Wiedermann CJ et al. Non-overt disseminated intravascular coagulation scoring for critically ill patients: the impact of antithrombin levels. Thromb. Haemost. 101(4), 696–705 (2009).
   PubMed Web of Science ®Google Scholar
• Toh CH, Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul. Fibrinolysis 16(1), 69–74 (2005).
   PubMed Web of Science ®Google Scholar
• Wada H, Hatada T, Okamoto K et al.; Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am. J. Hematol. 85(9), 691–694 (2010).
   PubMed Web of Science ®Google Scholar
• Müller-Berghause G, Blombäck M, Ten Cate JW. Attempts to define disseminated intravascular coagulation.In: DIC: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. Müller-Berghause G, Blombäck M, Madlener K, Ten Cate JW (Eds). Elsevier Science Publishers BV, Amsterdam, The Netherlands, 3–8 (1993).
   Google Scholar
• Müller-Berghaus G, Ten Cate H, Levi M. Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. Thromb. Haemost. 86, 1327–1330 (2001).
   PubMed Web of Science ®Google Scholar
• Wada H, Nagano T, Tomeoku M et al. Coagulant and fibrinolytic activities in the leukemic cell lysates. Thromb. Res. 30(4), 315–322 (1983).
   PubMed Web of Science ®Google Scholar
• Wada H, Wakita Y, Shiku H. Tissue factor expression in endothelial cells in health and disease. Blood Coagul. Fibrinolysis 6(Suppl. 1), S26–S31 (1995).
   Google Scholar
• Wada H, Kumeda Y, Ogasawara Z et al. Plasminogen-activators and their inhibitors in leukemic cell homogenates. Am. J. Hematol. 42(2), 166–170 (1993).
   PubMed Web of Science ®Google Scholar
• Wojtukiewicz MZ, Sierko E, Zacharski LR, Zimnoch L, Kudryk B, Kisiel W. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin. Thromb. Hemost. 29(3), 291–300 (2003).
   PubMed Web of Science ®Google Scholar
• Faulk WP, Labarrere CA, Carson SD. Tissue factor: identification and characterization of cell types in human placentae. Blood 76(1), 86–96 (1990).
   PubMed Web of Science ®Google Scholar
• Wada H, Kumeda Y, Ogasawara Z et al. Stimulation of tissue type plasminogen-activator by leukemic cell homogenates. Blood Coag Fibr. 4, 591–598 (1993).
   PubMed Web of Science ®Google Scholar
• Spencer DC, Pienaar NL, Atkinson PM. Disturbances of blood coagulation associated with Salmonella typhi infections. J. Infect. 16(2), 153–161 (1988).
   PubMed Web of Science ®Google Scholar
• Taylor FB Jr, Chang A, Ruf W et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ. Shock 33(3), 127–134 (1991).
   PubMedGoogle Scholar
• Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 91(5), 1609–1615 (1998).
   PubMed Web of Science ®Google Scholar
• Creasey AA, Chang AC, Feigen L, Wün TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest. 91(6), 2850–2860 (1993).
   PubMed Web of Science ®Google Scholar
• Wada H, Tamaki S, Tanigawa M et al. Plasma levels of IL-1β in disseminated intravascular coagulation. Thromb Haemost. 65, 364–368 (1991).
   PubMed Web of Science ®Google Scholar
• Wada H, Ohiwa M, Kaneko T et al. Plasma level of tumor necrosis factor in disseminated intravascular coagulation. Am. J. Hematol. 37(3), 147–151 (1991).
   PubMed Web of Science ®Google Scholar
• Lien E, Means TK, Heine H et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J. Clin. Invest. 105(4), 497–504 (2000).
   PubMed Web of Science ®Google Scholar
• Thomas JA. Toll genes and responsiveness to bacterial endotoxin. N. Engl. J. Med. 342, 664–665 (2000).
   PubMedGoogle Scholar
• Sase T, Wada H, Kamikura Y et al. Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. Thromb. Haemost. 92(1), 132–139 (2004).
   PubMed Web of Science ®Google Scholar
• Ono T, Mimuro J, Madoiwa S et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 107(2), 528–534 (2006).
   PubMed Web of Science ®Google Scholar
• Hyun J, Kim HK, Kim JE et al. Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation. Thromb. Res. 124(1), 75–79 (2009).
   PubMed Web of Science ®Google Scholar
• Habe K, Wada H, Ito-Habe N et al. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb. Res. 129(5), 598–602 (2012).
   PubMed Web of Science ®Google Scholar
• Hatada T, Wada H, Nobori T et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb. Haemost. 94(5), 975–979 (2005).
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang X, Pelayo R et al. Extracellular histones are major mediators of death in sepsis. Nat. Med. 15(11), 1318–1321 (2009).
   PubMed Web of Science ®Google Scholar
• Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 95(5), 1680–1686 (2000).
   PubMed Web of Science ®Google Scholar
• Taylor FB Jr, Kinasewitz GT, Lupu F. Pathophysiology, staging and therapy of severe sepsis in baboon models. J. Cell. Mol. Med. 16(4), 672–682 (2012).
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl. Haematol. 49, 265–275 (1983).
   PubMedGoogle Scholar
• Wada H, Gabazza EC, Asakura H et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am. J. Hematol. 74(1), 17–22 (2003).
   PubMed Web of Science ®Google Scholar
• Takemitsu T, Wada H, Hatada T et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb. Haemost. 105(1), 40–44 (2011).
   PubMed Web of Science ®Google Scholar
• Wada H, Wakita Y, Nakase T et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb. Haemost. 74(3), 848–852 (1995).
   PubMed Web of Science ®Google Scholar
• Wada H, Minamikawa K, Wakita Y et al. Hemostatic study before onset of disseminated intravascular coagulation. Am. J. Hematol. 43(3), 190–194 (1993).
   PubMed Web of Science ®Google Scholar
• Wada H, Wakita Y, Nakase T et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am. J. Hematol. 51(4), 255–260 (1996).
   PubMed Web of Science ®Google Scholar
• Kawasugi K, Wada H, Hatada T et al.; Japanese Society of Thrombosis Hemostasis/DIC Subcommittee. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb. Res. 128(2), 186–190 (2011).
   PubMed Web of Science ®Google Scholar
• Wada H, Mori Y, Shimura M et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am. J. Hematol. 58(3), 189–194 (1998).
   PubMed Web of Science ®Google Scholar
• Hatada T, Wada H, Kawasugi K et al.; Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Analysis of the cutoff values in fibrin-related markers for the diagnosis of overt DIC. Clin. Appl. Thromb. Hemost. 18(5), 495–500 (2012).
   PubMed Web of Science ®Google Scholar
• Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22(7), 707–710 (1996).
   PubMed Web of Science ®Google Scholar
• Polderman KH, Girbes AR. Drug intervention trials in sepsis: divergent results. Lancet 363(9422), 1721–1723 (2004).
   PubMed Web of Science ®Google Scholar